Biological and novel therapies for inflammatory bowel disease in children

Pediatric Clinics of North America

Volumn 49, Issue 1, 2002, Pages 1-25

  Mamula, Petar ^a   Mascarenhas, Maria R ^a   Baldassano, Robert N ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; MESALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CROHN DISEASE; DIET THERAPY; DISEASE CLASSIFICATION; HUMAN; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 0036157731     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(03)00106-8     Document Type: Review

References (90)

1. A multicenter study of infliximab (anti-TNF alpha antibody) in the treatment of children with active Crohn's disease
2. The role of tumor necrosis factor in health and disease
3. Serum basic fibroblast growth factor in pediatric Crohn's disease: Implications for wound healing
4. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
5. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease
6. Beneficial effects of growth hormone combined with parenteral nutrition in the management of inflammatory bowel disease: An experimental study
7. Infliximab is an effective therapeutic agent for ulcerative colitis
8. Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease
9. Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy
10. Tumour-necrosis-factor antibody treatment in Crohn's disease
11. Etanercept (TNF receptor fusion protein) is effective and well tolerated in active refractory Crohn's disease: Results of a single center pilot trial
12. Nutritional issues in inflammatory bowel disease
13. Low molecular weight heparin significantly ameliorates experimental colitis
14. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
15. Taming TNF: Strategies to restrain this proinflammatory cytokine
16. Helminthic parasites inhibit spontaneous colitis in IL-10 deficient mice
17. Does the failure to acquire helminthic parasites predispose to Crohn's disease?
18. Treatment of ulcerative colitis with an engineered human anti-TNF-α antibody CDP 571
19. Treatment of corticosteroid-resistant ulcerative colitis with heparin: A report of 16 cases
20. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
21. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease: The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group
22. Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn's disease
23. Inflammatory bowel disease: Etiology and pathogenesis
24. Heparin therapy for ulcerative colitis
25. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease
26. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice
27. Paradoxical response to heparin in 10 patients with ulcerative colitis
28. A randomised, double blind, placebo controlled, pan-European study of a recombinant humanised antibody to alpha-4 integrin in moderate to severely active Crohn's disease
29. Randomised double-blind placebo-controlled trial of recombinant humanised antibody to alpha4 integrin in active Crohn's disease
30. Treatment of active ulcerative colitis with a recombinant humanised antibody to alpha4 integrin
31. Nutrition and inflammatory bowel disease
32. Maintenance infliximab is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the Accent I trial
33. Delayed hypersensitivity to infliximab reinfusion after 2-4 year interval without treatment
34. Therapy with recombinant growth hormone in children with Crohn disease and growth failure
35. Treatment of chronic enteritis in glycogen storage disease type IB with granulocyte colony-stimulating factor
36. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
37. Use of infliximab in the treatment of Crohn's disease in children and adolescents
38. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis
39. Immune stimulation in Crohn's disease: Safety and efficacy of rhuGM-CSF for the treatment of active Crohn's disease
40. A multi-center, randomized, controlled trial of heparin for the treatment of ulcerative colitis
41. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
42. Treatment of ulcerative colitis (UC) with PPAR-gamma ligands: Preliminary results of a pilot study
43. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease
44. Effect of administered human growth hormone on growth retardation in inflammatory bowel disease
45. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells
46. Inhibitors of tumor necrosis factor for rheumatoid arthritis
47. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease
48. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease
49. Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor
50. Antibodies to interleukin 12 abrogate established experimental colitis in mice
51. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
52. Tumor necrosis factor and IL-1 beta expression in pediatric patients with inflammatory bowel disease
53. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis
54. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody
55. Infliximab for the treatment of fistulas in patients with Crohn's disease
56. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats
57. Brief report: Treatment of chronic inflammatory bowel disease in glycogen storage disease type Ib with colony-stimulating factors
58. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
59. Malignancy following Remicade therapy: Incidence and characteristics
60. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial
61. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
62. A randomized, double-blind, placebo-controlled trial of subcutaneous etanercept (p75 soluble tumor necrosis factor: FC fusion protein) in the treatment of moderate to severe Crohn's disease
63. Therapy of inflammatory bowel disease
64. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
65. Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC)
66. A randomized, double-masked, placebo-controlled study of recombinant human interleukin-11 in Crohn's disease subjects not receiving prednisone
67. Long term safety of infliximab
68. A safety and efficacy study of recombinant human interleukin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn's disease (CACD)
69. Safety and tolerance of rHuIL-10 in patients with mild/moderate active ulcerative colitis
70. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
71. Alterations of monocyte function in patients with growth hormone (GH) deficiency: Effect of substitutive GH therapy
72. A preliminary study of growth hormone therapy for Crohn's disease
73. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
74. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
75. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
76. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy
77. LMWH for the treatment of mild to moderately active steroid refractory/dependent UC-an independent, multicenter, randomised, controlled trial
78. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis
79. Therapeutic uses of heparin beyond its traditional role as an anticoagulant
80. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
81. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
82. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
83. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease
84. Treatment of ulcerative colitis with thalidomide
85. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha
86. Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease
87. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
88. A randomized, placebo-controlled trial of an antisense ICAM-1 inhibitor (ISIS2302) in steroid-dependent Crohn's disease showed clinical improvement at high serum levels
89. Hemostasis and heparin therapy in non-specific ulcerative colitis
90. The use of anticoagulants in combined therapy of non-specific ulcerative colitis